Metabolism of bromobenzene to glutathione adducts in lung slices from mice treated with pneumotoxicants

The Key Role of GSH in Keeping the Redox Balance in Mammalian Cells: Mechanisms and Significance of GSH in Detoxification via Formation of Conjugates

Glutathione (GSH) is a ubiquitous tripeptide that is biosynthesized in situ at high concentrations (1-5 mM) and involved in the regulation of cellular homeostasis via multiple mechanisms. The main known action of GSH is its antioxidant capacity, which aids in maintaining the redox cycle of cells. To this end, GSH peroxidases contribute to the scavenging of various forms of ROS and RNS. A generally underestimated mechanism of action of GSH is its direct nucleophilic interaction with electrophilic compounds yielding thioether GSH S-conjugates. Many compounds, including xenobiotics (such as NAPQI, simvastatin, cisplatin, and barbital) and intrinsic compounds (such as menadione, leukotrienes, prostaglandins, and dopamine), form covalent adducts with GSH leading mainly to their detoxification. In the present article, we wish to present the key role and significance of GSH in cellular redox biology. This includes an update on the formation of GSH-S conjugates or GSH adducts with emphasis given to the mechanism of reaction, the dependence on GST (GSH S-transferase), where this conjugation occurs in tissues, and its significance. The uncovering of the GSH adducts' formation enhances our knowledge of the human metabolome. GSH-hematin adducts were recently shown to have been formed spontaneously in multiples isomers at hemolysates, leading to structural destabilization of the endogenous toxin, hematin (free heme), which is derived from the released hemoglobin. Moreover, hemin (the form of oxidized heme) has been found to act through the Kelch-like ECH associated protein 1 (Keap1)-nuclear factor erythroid 2-related factor-2 (Nrf2) signaling pathway as an epigenetic modulator of GSH metabolism. Last but not least, the implications of the genetic defects in GSH metabolism, recorded in hemolytic syndromes, cancer and other pathologies, are presented and discussed under the framework of conceptualizing that GSH S-conjugates could be regarded as signatures of the cellular metabolism in the diseased state.

Development of a Novel AOP for Cyp2F2-Mediated Lung Cancer in Mice

Traditional methods for carcinogenicity testing rely heavily on the rodent bioassay as the standard for identification of tumorigenic risk. As such, identification of species-specific outcomes and/or metabolism are a frequent argument for regulatory exemption. One example is the association of tumor formation in the mouse lung after exposure to Cyp2F2 ligands. The adverse outcome pathway (AOP) framework offers a theoretical platform to address issues of species specificity that is consistent, transparent, and capable of integrating data from new approach methodologies as well as traditional data streams. A central premise of the AOP concept is that pathway progression from the molecular initiating event (MIE) implies a definable “response-response” (R-R) relationship between each key event (KE) that drives the pathway towards a specific adverse outcome (AO). This article describes an AOP for lung cancer in the mouse from an MIE of Cyp2F2-specific reactive metabolite formation, advancing through KE that include protein and/or nucleic acid adducts, diminished Club Cell 10 kDa (CC10) protein expression, hyperplasia of CC10 deficient Club cells, and culminating in the AO of mixed-cell tumor formation in the distal airways. This tumor formation is independent of route of exposure and our AOP construct is based on overlapping mechanistic events for naphthalene, styrene, ethyl benzene, isoniazid, and fluensulfone in the mouse. This AOP is intended to accelerate the explication of an apparent mouse-specific outcome and serve as a starting point for a quantitative analysis of mouse-human differences in susceptibility to the tumorigenic effects of Cyp2F2 ligands.

Precision-cut tissue slices: applications in pharmacology and toxicology

Almost a decade has passed since the first paper describing the isolation and maintenance of precision-cut liver slices produced using a mechanical tissue slicer was published (1). Although tissue slices of various organs have been employed as an in vitro system for several decades, the lack of reproducibility within the slices and the relatively limited viability of the tissue preparations has prevented a widespread acceptance of the technique. The production of an automated slicer, capable of reproducibly producing relatively thin slices of tissue, as well as the development of a dynamic organ culture system, overcame several of these obstacles. Since that time, significant advances in the methods to produce and culture tissue slices have been made, as well as the application of the technique to several other organs, including kidney, lung and heart. This review will i) summarize the historical use of tissue slices prior to the development of the precision-cut tissue slice system; ii) briefly analyze current methods to produce precision-cut liver, kidney, lung and heart slices; and iii) discuss the applications of this powerful in vitro system to the disciplines of pharmacology and toxicology.

Species differences in short term toxicity from inhalation exposure to bromobenzene

Lung, liver and kidney injury were studied in mice, rats and rabbits 48 h after termination of a 4 h inhalation exposure to bromobenzene vapour (250-3400 ppm). Light and electron microscopy of lung tissue revealed injury to Clara cells and adjacent epithelium in mouse bronchioli (bromobenzene concentration 250 ppm and 1000 ppm) and to Clara cells of rat bronchi and bronchioli (1000 ppm bromobenzene) and of rabbit bronchi (2500 ppm and 3400 ppm). Histological and clinicochemical indices of liver damage were found in the same animals, whereas kidney toxicity was observed in mice (two out of ten showed tubular necrosis and elevated concentration of plasma urea) and rats (all had elevated plasma concentrations of creatinine) exposed to 1000 ppm bromobenzene. Inhalation exposure thus produced less kidney injury than expected from previous studies with equimolar doses given intraperitoneally. The mouse was the most severely affected species, followed by the rat, and lastly the rabbit. The animal susceptibility could not be ranked according to the rate of 14C-bromobenzene covalent binding in lung or liver, but it was inversely related to the rate of N-demethylation of benzphetamine (indicative of P450IIB activity) in both lung and liver microsomal preparations. Differences in a P450 mediated detoxification could therefore be of importance in species variability to bromobenzene injury.

Studies on the metabolism of the pneumotoxin O,S,S-trimethyl phosphorodithioate--II. Lung and liver slices

The metabolism of O,S,S-trimethyl phosphorodithioate (OSSMe), a pneumotoxic impurity in some organophosphorus insecticides, was investigated by incubating rat lung and liver slices with 1 mM OSSMe, labelled with 3H or 14C on one of its thiolo-methyl (CH3S-) groups. Protein bound radioactivity was higher in lung slices than in liver slices. In lung slices the predominant diester produced was O,S-dimethyl phosphorothioate (OSMeO-), whereas in liver slices it was S,S-dimethyl phosphorodithioate (SSMeO-). Other studies had shown binding of radioactivity and OSMeO- production to be cytochrome P-450-dependent processes in microsomes and SSMeO- production to result from the action of cytosolic glutathione-S-transferase on OSSMe. Preincubation of slices with 10(-5) M paraoxon did not influence the amount of protein-bound radioactivity, suggesting that binding of radioactivity did not simply result from protein phosphorylation. Pretreatments of the rats with O,O,O-trimethyl phosphorothioate [OOOMe(S) 0.5, 2.5 and 12.5 mg/kg p.o.], with p-xylene (1 g/kg, i.p.) or with bromophos (5.3 mg/kg, i.p.) which all protect against the lung toxicity of OSSMe probably by inhibiting pulmonary mixed-function oxidase, also led to significant decreases in both protein binding of radioactivity and OSMeO- production in lung slices, but not in liver slices. These results show that tissue slices are a convenient system for investigating xenobiotic metabolism in the lung and they suggest that the susceptibility of the lung to OSSMe probably results from a relatively high rate of activation, coupled with a relatively low rate of metabolism by non-toxic pathways and/or removal of reactive metabolites in some lung cells, possibly the alveolar type I cells.

Studies on the mechanism of enhancement of butylated hydroxytoluene-induced mouse lung toxicity by butylated hydroxyanisole

The studies described in this report were designed to probe possible mechanisms whereby butylated hydroxyanisole (BHA) is able to enhance butylated hydroxytoluene (BHT)-induced mouse lung toxicity. In experiments with mouse lung slices, BHA enhanced the covalent binding of BHT to protein, indicating that the interaction between BHA and BHT takes place in the lung. Subcutaneous administration of either BHA (250 mg/kg) or diethyl maleate (DEM, 1 ml/kg) to male CD-1 mice produced a similar enhancement of BHT-induced lung toxicity. In contrast to DEM, the administration of BHA (250 or 1500 mg/kg) did not decrease mouse lung glutathione levels, suggesting that the effect of BHA is not due to the depletion of glutathione levels. We previously observed that in the presence of model peroxidases a unique interaction occurs between BHA and BHT, resulting in the increased metabolic activation of BHT. Upon the addition of hydrogen peroxide or various hydroperoxides to mouse lung microsomes, BHA significantly increased the covalent binding of BHT to protein. BHA also stimulated the rate of formation of hydrogen peroxide by 4.7-fold in mouse lung microsomes. Likewise, hydrogen peroxide resulting from the NADPH cytochrome P-450 (c) reductase-catalyzed redox cycling of tert-butylhydroquinone, a microsomal metabolite of BHA, supported the peroxidase-dependent BHA-enhanced formation of BHT-quinone methide. These results suggest that BHA could facilitate the activation of BHT in the lung as a result of both the increased formation of hydrogen peroxide and the subsequent peroxidase-dependent formation of BHT-quinone methide from the direct interaction of BHA with BHT.

Protection by dimethylsulfoxide against acetaminophen-induced hepatic, but not respiratory toxicity in the mouse

Dimethylsulfoxide (DMSO) is used as a vehicle for the administration of compounds that are difficult to solubilize. Acetaminophen (AP), typically administered ip in hot basic saline, dissolves readily in DMSO. However, since DMSO acts as a free radical scavenger in vitro, and since AP toxicity may be mediated through oxidative stress, we examined the possibility that DMSO might protect against AP toxicity. Survival of mice 96 hr after AP (900 mg/kg ip) was increased from 10 to 60% by concomitant DMSO administration (4 g/kg sc). Adult female Swiss inbred mice given AP (800 mg/kg ip in hot basic saline) exhibited severe centrilobular hepatic necrosis, pulmonary nonciliated bronchiolar epithelial (Clara cell) necrosis and nasal epithelial necrosis. DMSO (8 g/kg 50% in saline) protected against AP hepatotoxicity, whether administered prophylactically (14.5 and 2.5 hr before AP), concomitantly with AP, or antidotally (30 or 60 min post-AP). No treatment protected against pulmonary Clara cell damage. Nor did pretreatment with DMSO protect against AP-induced necrosis of nasal epithelium. Other treatment regimes were not evaluated for their effect on nasal epithelial toxicity. Since DMSO protection is tissue specific, it does not appear to be mediated by a nonspecific mechanism, such as scavenging of free radicals. Six hours after AP, glutathione (GSH) levels had dropped significantly in liver, but not in lung. AP-induced loss of hepatic GSH was slowed by DMSO even in the presence of BSO, an inhibitor of GSH synthesis. These findings are consistent with decreased utilization of GSH, due to decreased bioactivation of AP or decreased turnover of GSH.

Protection by methylprednisolone against butylated hydroxytoluene-induced pulmonary damage and impairment of microsomal monooxygenase activities in the mouse: lack of effect on fibrosis

The effects of the synthetic corticosteroid methylprednisolone (MP; 30 mg/kg, s.c. given twice daily for 3 days), on the pneumotoxic effects of a single dose of butylated hydroxytoluene (BHT; 400 mg/kg, i.p.) over a 10 day experimental period was investigated in male C57BL/6N mice. BHT alone caused time-dependent alveolar hypercellularity, inflammatory infiltration, alveolar septal thickening and hypercellularity of the bronchiolar epithelium, reaching a maximum by day 5 with some degree of recovery by day 10. The pulmonary monooxygenase activities reflected the degree of alveolar damage and Clara cell abnormality with time; reductions in monooxygenase activities occurred and minimum levels (7-15% of control) were reached by day 5 and again a trend towards recovery by day 10. MP administered 0, 24 and 48 hr after BHT treatment partially protected mice from these effects of BHT in a distinctly time-dependent fashion; the degree of protection decreased as the time between BHT challenge and MP treatment increased. Although MP alone did not morphologically affect Clara and alveolar cells, it increased, decreased or had no effect on the monooxygenase activities. About 25% of the mice that received BHT alone died by day 5 and 50% by day 10. MP completely blocked the lethal effects of BHT by day 5 and reduced the deaths to between 15% and 25% by day 10. Interestingly, MP did not protect against the BHT-induced pulmonary fibrosis, measured as total lung hydroxyproline content, irrespective of the time between BHT challenge and MP treatment. MP alone did not cause any deaths nor increase lung hydroxyproline content.

Adducts of 3-methylindole and glutathione: species differences in organ-selective bioactivation

Lung and liver microsomes of several species were evaluated for potential to form activated metabolites of 3-methylindole (3MI). Microsomes were incubated with [14C]3MI and glutathione (GSH). Electrophilic 3MI metabolites were trapped and quantitated as GSH adducts by HPLC, and by determining the amounts of activated intermediates which became covalently bound to microsomal protein. The highest rates of 3MI-GSH adduct formation by the lung were detected in microsomes of the goat, followed in decreasing order by pulmonary microsomes from the horse, monkey, mouse, and rat, respectively. In contrast, hepatic 3MI-GSH adduct production was highest in microsomes from the rat, followed by mouse, monkey, goat, and horse microsomes, respectively. These results suggest that the species and organ-selective toxicity of 3MI are primarily caused by differences in rates of oxidative metabolism of 3MI to an electrophilic intermediate.